Praetorian PR LLC Raises Holdings in INmune Bio, Inc. (NASDAQ:INMB)

Praetorian PR LLC lifted its position in shares of INmune Bio, Inc. (NASDAQ:INMB) by 61.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 780,800 shares of the company’s stock after buying an additional 295,800 shares during the period. INmune Bio comprises about 1.6% of Praetorian PR LLC’s investment portfolio, making the stock its 8th largest holding. Praetorian PR LLC’s holdings in INmune Bio were worth $4,209,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Fermata Advisors LLC boosted its position in INmune Bio by 8.5% during the 2nd quarter. Fermata Advisors LLC now owns 34,140 shares of the company’s stock worth $301,000 after acquiring an additional 2,689 shares during the last quarter. Westside Investment Management Inc. raised its holdings in shares of INmune Bio by 31.8% in the second quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock valued at $400,000 after purchasing an additional 10,950 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of INmune Bio by 124.6% in the second quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after purchasing an additional 32,511 shares in the last quarter. Rhumbline Advisers acquired a new position in INmune Bio during the second quarter worth $121,000. Finally, Marshall Wace LLP boosted its holdings in INmune Bio by 332.1% during the second quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after purchasing an additional 89,091 shares during the last quarter. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Price Performance

Shares of INMB opened at $5.05 on Friday. The company has a market cap of $111.96 million, a PE ratio of -2.32 and a beta of 1.85. The firm has a 50-day moving average of $5.34 and a 200-day moving average of $7.08. INmune Bio, Inc. has a one year low of $4.45 and a one year high of $14.74.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.11). INmune Bio had a negative return on equity of 117.48% and a negative net margin of 26,333.59%. During the same period in the prior year, the firm posted ($0.48) EPS. Analysts expect that INmune Bio, Inc. will post -2.24 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Scotiabank began coverage on shares of INmune Bio in a research report on Thursday, August 22nd. They set a “sector outperform” rating and a $22.00 price target on the stock. Alliance Global Partners started coverage on INmune Bio in a report on Monday, October 21st. They set a “buy” rating and a $20.00 target price on the stock. Finally, Raymond James initiated coverage on INmune Bio in a research note on Friday, September 27th. They issued an “outperform” rating and a $18.00 price target for the company.

Insider Transactions at INmune Bio

In related news, CEO Raymond Joseph Tesi acquired 15,380 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were bought at an average cost of $6.38 per share, with a total value of $98,124.40. Following the completion of the transaction, the chief executive officer now directly owns 1,554,106 shares of the company’s stock, valued at $9,915,196.28. This trade represents a 1.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO David J. Moss bought 10,000 shares of INmune Bio stock in a transaction that occurred on Monday, September 30th. The shares were bought at an average cost of $5.29 per share, with a total value of $52,900.00. Following the acquisition, the chief financial officer now directly owns 1,285,869 shares in the company, valued at $6,802,247.01. This trade represents a 0.78 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders acquired 33,070 shares of company stock worth $200,087. 35.20% of the stock is owned by company insiders.

INmune Bio Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.